Gijbert Veerman

Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

P. Beale, J. Wanders, N. Pavlidis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.